YIhao Tian

Dr. YIhao Tian


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CHChengjun Hu
Chengjun Hu
YTYIhao Tian
YIhao Tian
HXHongxin Xu
Hongxin Xu
BPBo Pan
Bo Pan
ETErin M. Terpstra
Erin M. Terpstra
Xuejun WangXuejun Wang
Xuejun Wang
The ubiquitin-proteasome system (UPS) degrades a protein molecule via 2 main steps: ubiquitination and proteasomal degradation. Extraproteasomal ubiquitin receptors are thought to couple the 2 steps, but this proposition has not been tested in vivo with vertebrates. More importantly, impaired UPS performance plays a major role in cardiac pathogenesis, including myocardial ischemia-reperfusion injury (IRI), but the molecular basis of UPS impairment remains poorly understood. Ubiquilin1 is a bona fide extraproteasomal ubiquitin receptor. Here, we report that mice with a cardiomyocyte-restricted knockout of Ubiquilin1 (Ubqln1-CKO mice) accumulated a surrogate UPS substrate (GFPdgn) and increased myocardial ubiquitinated proteins without altering proteasome activities, resulting in late-onset cardiomyopathy and a markedly shortened life span. When subject to regional myocardial ischemia-reperfusion, young Ubqln1-CKO mice showed substantially exacerbated cardiac malfunction and enlarged infarct size, and conversely, mice with transgenic Ubqln1 overexpression displayed attenuated IRI. Furthermore, Ubqln1 overexpression facilitated proteasomal degradation of oxidized proteins and the degradation of a UPS surrogate substrate in cultured cardiomyocytes without increasing autophagic flux. These findings demonstrate that Ubiquilin1 is essential to cardiac ubiquitination-proteasome coupling and that an inadequacy in the coupling represents a major pathogenic factor for myocardial IRI; therefore, strategies to strengthen coupling have the potential to reduce IRI.

1 January 2020 in International Journal of Biological Sciences
Verified
Journal Article
Open access
LXLiu Xu
Liu Xu
JWJing Wang
Jing Wang
XYXiaoning Yuan
Xiaoning Yuan
SYShuhua Yang
Shuhua Yang
XXXiaolong Xu
Xiaolong Xu
YTYIhao Tian
YIhao Tian
Previous studies have demonstrated that the antitumor potential of IU1 (a pharmacological compound), which was mediated by selective inhibition of proteasome-associated deubiquitinase ubiquitin-specific protease 14 (USP14). However, the underlying molecular mechanisms remain elusive. It has been well established that mdm2 (Murine double minute 2) gene was amplified and/or overexpressed in a variety of human neoplasms, including cervical cancer. Furthermore, MDM2 is critical to cervical cancer development and progression. Relatively studies have reported that USP15 and USP7 stabilized MDM2 protein levels by removing its ubiquitin chain. In the current study, we studied the cell proliferation status after IU1 treatment and the USP14-MDM2 protein interaction in cervical cancer cells. This study experimentally revealed that IU1 treatment reduced MDM2 protein expression in HeLa cervical cancer cells, along with the activation of autophagy-lysosomal protein degradation and promotion of ubiquitin-proteasome system (UPS) function, thereby blocked G0/G1 to S phase transition, decreased cell growth and triggered cell apoptosis. Thus, these results indicate that IU1 treatment simultaneously targets two major intracellular protein degradation systems, ubiquitin-proteasome and autophagy-lysosome systems, which leads to MDM2 degradation and contributes to the antitumor effect of IU1.

26 March 2024 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Open access
XYXiao-Ning Yuan
Xiao-Ning Yuan
YSYou-Cheng Shao
You-Cheng Shao
XGXiao-Qing Guan
Xiao-Qing Guan
QLQin Liu
Qin Liu
MCMeng-Fei Chu
Meng-Fei Chu
LWLei Wei
Lei Wei
The carcinogenic transcription factor c-Myc is the most aggressive oncogene, which drive malignant transformation and dissemination of triple-negative breast cancer (TNBC). Recruitment of many cofactors, especially WDR5, a protein that nucleates H3K4me chromatin modifying complexes, play a pivotal role in regulating c-Myc-dependent gene transcription, a critical process for c-Myc signaling to function in a variety of biological and pathological contexts. For this reason, interrupting the interaction between c-Myc and the transcription cofactor WDR5 may become the most promising new strategy for treating c-Myc driven TNBC. Immunoprecipitation and mass spectrometry (IP-MS) is used to screen proteins that bind c-Myc/WDR5 interactions. The interaction of METTL3 with c-Myc/WDR5 in breast cancer tissues and TNBC cells was detected by Co-IP and immunofluorescence. Subsequently, we further analyzed the influence of METTL3 expression on c-Myc/WDR5 protein expression and its interaction stability by Western blot and Co-IP. The correlation between METTL3 and c-Myc pathway was analyzed by ChIP-seq sequencing and METTL3 knockdown transcriptome data. The effect of METTL3 expression on c-Myc transcriptional activity was detected by ChIP-qPCR and Dual Luciferase Reporter. At the same time, the overexpression vector METTL3-MUT (m6A) was constructed, which mutated the methyltransferase active site (Aa395-398, DPPW/APPA), and further explored whether the interaction between METTL3 and c-Myc/WDR5 was independent of methyltransferase activity. In addition, we also detected the changes of METTL3 expression on TNBC's sensitivity to small molecule inhibitors such as JQ1 and OICR9429 by CCK8, Transwell and clonal formation assays. Finally, we further verified our conclusions in spontaneous tumor formation mouse MMTV-PyMT and nude mouse orthotopic transplantation tumor models. METTL3 was found to bind mainly to c-Myc/WDR5 protein in the nucleus. It enhances the stability of c-Myc/WDR5 interaction through its methyltransferase independent mechanism, thereby enhancing the transcriptional activity of c-Myc on downstream glucose metabolism genes. Notably, the study also confirmed that METTL3 can directly participate in the transcription of glucose metabolism genes as a transcription factor, and knockdown METTL3 enhances the drug sensitivity of breast cancer cells to small molecule inhibitors JQ1 and OICR9429. The study was further confirmed by spontaneous tumor formation mouse MMTV-PyMT and nude mouse orthotopic transplantation tumor models. METTL3 binds to the c-Myc/WDR5 protein complex and promotes glycolysis, which plays a powerful role in promoting TNBC progression. Our findings further broaden our understanding of the role and mechanism of action of METTL3, and may open up new therapeutic avenues for effective treatment of TNBC with high c-Myc expression.

1 January 2023
Verified
Journal Article
Closed access
XYXiao-Ning Yuan
Xiao-Ning Yuan
QLQin Liu
Qin Liu
YSYou-Cheng Shao
You-Cheng Shao
XGXiao-Qing Guan
Xiao-Qing Guan
ZYZe-Lin Yang
Ze-Lin Yang
LWLei Wei
Lei Wei

7 November 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
LGLun Gao
Lun Gao
XJXiongfei Jing
Xiongfei Jing
QHQiuwei Hua
Qiuwei Hua
ZLZhiyang Li
Zhiyang Li
PLPan Lei
Pan Lei
QCQiang Cai
Qiang Cai

27 November 2025 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
QLQifan Luo
Qifan Luo
LCLe Chen
Le Chen
SZSai Zhao
Sai Zhao
LWLei Wei
Lei Wei
YTYIhao Tian
YIhao Tian
JZJingwei Zhang
Jingwei Zhang
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor response to chemotherapy. Fewer than 40% of patients achieve a c